STK11基因突变与非小细胞肺癌免疫治疗相关性研究进展

Correlation Between STK11 Gene Mutation and Immunotherapy of Non-small Cell Lung Cancer

肺癌是最常见的恶性肿瘤之一。在全球范围内,肺癌的发病率及死亡率都极高且呈上升趋势。近年来,免疫检查点抑制剂(ICIs)在晚期非小细胞型肺癌治疗中产生了显著的生存优势,然而对于驱动基因阳性的非小细胞肺癌患者,免疫检查点抑制剂疗效不佳。但一些抑癌基因可以通过突变或缺失等方式对免疫治疗产生不同程度的影响,其中丝氨酸/苏氨酸激酶11(STK11)基因突变与PD-1/PD-L1免疫检查点抑制剂有效性密切相关,研究发现STK11突变与免疫细胞浸润减少、PD-L1低表达和对PD-L1抑制反应差有关。本文就非小细胞肺癌中STK11基因突变与免疫治疗相关性的研究进展作一综述。

Lung cancer is one of the most common malignant tumors.Globally,the incidence and mortality of lung cancer are very high and on the rise.In recent years,immune checkpoint inhibitors(ICIs)have a significant survival advantage in treating advanced NSCLC.However,for NSCLC patients with positive driver genes,ICIs are not effective.But some tumor suppressor genes have varying degrees of impact on immunotherapy through mutations or deletions.Among them,serine/threonine kinase 11(STK11)gene mutations are closely related to PD-1/PD-L1 ICIs.Studies have found that STK11 mutations are related to reduced immune cell infiltration,low PD-L1 expression and poor response to PD-L1 inhibition.This article reviews the research progress of the correlation between STK11 gene mutation and immunotherapy on NSCLC.